You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The financing round brings the total amount of funding for Micronoma, a developer of microbiome-based cancer detection technology, to $6.5 million.
The firm saw strong increases in international HIV sales of its OraQuick HIV Self-Test product in the quarter.
The companies are aiming to use microbial biomarkers to predict the development of precancerous adenomas and carcinomas.
MinIon sequencing identified pathogens and antimicrobial resistance genes in the gut of preterm infants with suspected necrotizing enterocolitis.
Tempus said that Akesogen's lab provides a range of testing services, including for inherited risk of cancer, microbiome profiling, whole-genome genotyping, and more.
The startup company will use the money to develop its microbial tests and AI-based software for surveillance and prevention of hospital-acquired infections.
The firm is also targeting a new market for oral fluid-based tests for drugs of abuse, projecting future growth due to new federal regulations.
OraSure will purchase Houston-based Diversigen, a microbiome and metagenomics consulting, sequencing, and data analysis service provider.
The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.
By examining metagenomic data of bacterial species in a patient's gut, the researchers aim to improve diagnosis and long-term nutritional intervention and treatment.